Status:
COMPLETED
Retrospective Study to Assess Real-Life Use of The Long Acting GnRH Agonist as Prostate Cancer Treatment
Lead Sponsor:
Chinese University of Hong Kong
Collaborating Sponsors:
Ipsen
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
It is a retrospective review of the electronic medical record of patients on long-acting triptorelin in Hong Kong.
Detailed Description
Prostate cancer is the second most prevalent cancer in men worldwide. Analogues of natural gonadotrophin releasing hormone (GnRH) are currently available in clinical practice to induce castration in s...
Eligibility Criteria
Inclusion
- Patients of Chinese heritage
- Prostate cancer patients with the following disease status:
- High-risk prostate cancer having hormonal therapy as neoadjuvant / adjuvant treatment for prostatectomy or radiotherapy; or
- Advanced / metastatic prostate cancer treated with long-term hormonal therapy; or
- After primary therapy (surgery or radiotherapy) with biochemical recurrence; or
- Castration-resistant prostate cancer status
- Received at least one dose of 6-month Gonadotropin-releasing Hormone Agonist triptorelin formulation
- Having at least 6 months of follow-up after administration of the 3-month to 6-month Gonadotropin-releasing Hormone Agonist triptorelin
Exclusion
- Nil
Key Trial Info
Start Date :
April 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 4 2024
Estimated Enrollment :
237 Patients enrolled
Trial Details
Trial ID
NCT06217770
Start Date
April 1 2023
End Date
January 4 2024
Last Update
January 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital
Shatin, Hong Kong